Global Anti-VEGF Therapy for Cancer Market Growth (Status and Outlook) 2026-2032
The global Anti-VEGF Therapy for Cancer market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Anti-VEGF Therapy for Cancer involves using drugs that inhibit vascular endothelial growth factor(VEGF),a protein crucial for blood vessel formation.By blockingVEGFor its receptors,these therapies aim to disrupt the formation of new blood vessels that tumors need to grow and metastasize.This approach helps to slow down or stop the progression of various cancers,such as colorectal,lung,and renal cell carcinoma.
United States market for Anti-VEGF Therapy for Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Anti-VEGF Therapy for Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Anti-VEGF Therapy for Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Anti-VEGF Therapy for Cancer players cover Sanofi, Eli Lilly, Roche, Bayer, Pfizer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “Anti-VEGF Therapy for Cancer Industry Forecast” looks at past sales and reviews total world Anti-VEGF Therapy for Cancer sales in 2025, providing a comprehensive analysis by region and market sector of projected Anti-VEGF Therapy for Cancer sales for 2026 through 2032. With Anti-VEGF Therapy for Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-VEGF Therapy for Cancer industry.
This Insight Report provides a comprehensive analysis of the global Anti-VEGF Therapy for Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Anti-VEGF Therapy for Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-VEGF Therapy for Cancer market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF Therapy for Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF Therapy for Cancer.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF Therapy for Cancer market by product type, application, key players and key regions and countries.
Segmentation by Type:
Anti-VEGF Therapy for Cancer involves using drugs that inhibit vascular endothelial growth factor(VEGF),a protein crucial for blood vessel formation.By blockingVEGFor its receptors,these therapies aim to disrupt the formation of new blood vessels that tumors need to grow and metastasize.This approach helps to slow down or stop the progression of various cancers,such as colorectal,lung,and renal cell carcinoma.
United States market for Anti-VEGF Therapy for Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Anti-VEGF Therapy for Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Anti-VEGF Therapy for Cancer is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Anti-VEGF Therapy for Cancer players cover Sanofi, Eli Lilly, Roche, Bayer, Pfizer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LPI (LP Information)' newest research report, the “Anti-VEGF Therapy for Cancer Industry Forecast” looks at past sales and reviews total world Anti-VEGF Therapy for Cancer sales in 2025, providing a comprehensive analysis by region and market sector of projected Anti-VEGF Therapy for Cancer sales for 2026 through 2032. With Anti-VEGF Therapy for Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-VEGF Therapy for Cancer industry.
This Insight Report provides a comprehensive analysis of the global Anti-VEGF Therapy for Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Anti-VEGF Therapy for Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-VEGF Therapy for Cancer market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-VEGF Therapy for Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-VEGF Therapy for Cancer.
This report presents a comprehensive overview, market shares, and growth opportunities of Anti-VEGF Therapy for Cancer market by product type, application, key players and key regions and countries.
Segmentation by Type:
- VEGF Inhibitors
- VEGFR Inhibitors
- Colorectal Cancer
- Non-small Cell Lung Cancer
- Renal Cell Carcinoma
- Cervical Cancer
- Medullary Thyroid Cancer
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Sanofi
- Eli Lilly
- Roche
- Bayer
- Pfizer
- Jiangsu Hengrui Pharmaceuticals
- Chia Tai Tianqing
- Novartis
- AstraZeneca
- Exelixis
- Boehringer Ingelheim
- Eisai
- Janssen Biotech
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-VEGF Therapy for Cancer Market Size (2021-2032)
2.1.2 Anti-VEGF Therapy for Cancer Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Anti-VEGF Therapy for Cancer by Country/Region (2021, 2025 & 2032)
2.2 Anti-VEGF Therapy for Cancer Segment by Type
2.2.1 VEGF Inhibitors
2.2.2 VEGFR Inhibitors
2.2.3 Anti-VEGF Therapy for Cancer Market Size by Type
2.2.3.1 Anti-VEGF Therapy for Cancer Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Anti-VEGF Therapy for Cancer Market Size Market Share by Type (2021-2026)
2.3 Anti-VEGF Therapy for Cancer Segment by Application
2.3.1 Colorectal Cancer
2.3.2 Non-small Cell Lung Cancer
2.3.3 Renal Cell Carcinoma
2.3.4 Cervical Cancer
2.3.5 Medullary Thyroid Cancer
2.3.6 Other
2.3.7 Anti-VEGF Therapy for Cancer Market Size by Application
2.3.7.1 Anti-VEGF Therapy for Cancer Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.7.2 Global Anti-VEGF Therapy for Cancer Market Size Market Share by Application (2021-2026)
3 ANTI-VEGF THERAPY FOR CANCER MARKET SIZE BY PLAYER
3.1 Anti-VEGF Therapy for Cancer Market Size Market Share by Player
3.1.1 Global Anti-VEGF Therapy for Cancer Revenue by Player (2021-2026)
3.1.2 Global Anti-VEGF Therapy for Cancer Revenue Market Share by Player (2021-2026)
3.2 Global Anti-VEGF Therapy for Cancer Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ANTI-VEGF THERAPY FOR CANCER BY REGION
4.1 Anti-VEGF Therapy for Cancer Market Size by Region (2021-2026)
4.2 Global Anti-VEGF Therapy for Cancer Annual Revenue by Country/Region (2021-2026)
4.3 Americas Anti-VEGF Therapy for Cancer Market Size Growth (2021-2026)
4.4 APAC Anti-VEGF Therapy for Cancer Market Size Growth (2021-2026)
4.5 Europe Anti-VEGF Therapy for Cancer Market Size Growth (2021-2026)
4.6 Middle East & Africa Anti-VEGF Therapy for Cancer Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026)
5.2 Americas Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026)
5.3 Americas Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-VEGF Therapy for Cancer Market Size by Region (2021-2026)
6.2 APAC Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026)
6.3 APAC Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026)
7.2 Europe Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026)
7.3 Europe Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-VEGF Therapy for Cancer by Region (2021-2026)
8.2 Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026)
8.3 Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ANTI-VEGF THERAPY FOR CANCER MARKET FORECAST
10.1 Global Anti-VEGF Therapy for Cancer Forecast by Region (2027-2032)
10.1.1 Global Anti-VEGF Therapy for Cancer Forecast by Region (2027-2032)
10.1.2 Americas Anti-VEGF Therapy for Cancer Forecast
10.1.3 APAC Anti-VEGF Therapy for Cancer Forecast
10.1.4 Europe Anti-VEGF Therapy for Cancer Forecast
10.1.5 Middle East & Africa Anti-VEGF Therapy for Cancer Forecast
10.2 Americas Anti-VEGF Therapy for Cancer Forecast by Country (2027-2032)
10.2.1 United States Market Anti-VEGF Therapy for Cancer Forecast
10.2.2 Canada Market Anti-VEGF Therapy for Cancer Forecast
10.2.3 Mexico Market Anti-VEGF Therapy for Cancer Forecast
10.2.4 Brazil Market Anti-VEGF Therapy for Cancer Forecast
10.3 APAC Anti-VEGF Therapy for Cancer Forecast by Region (2027-2032)
10.3.1 China Anti-VEGF Therapy for Cancer Market Forecast
10.3.2 Japan Market Anti-VEGF Therapy for Cancer Forecast
10.3.3 Korea Market Anti-VEGF Therapy for Cancer Forecast
10.3.4 Southeast Asia Market Anti-VEGF Therapy for Cancer Forecast
10.3.5 India Market Anti-VEGF Therapy for Cancer Forecast
10.3.6 Australia Market Anti-VEGF Therapy for Cancer Forecast
10.4 Europe Anti-VEGF Therapy for Cancer Forecast by Country (2027-2032)
10.4.1 Germany Market Anti-VEGF Therapy for Cancer Forecast
10.4.2 France Market Anti-VEGF Therapy for Cancer Forecast
10.4.3 UK Market Anti-VEGF Therapy for Cancer Forecast
10.4.4 Italy Market Anti-VEGF Therapy for Cancer Forecast
10.4.5 Russia Market Anti-VEGF Therapy for Cancer Forecast
10.5 Middle East & Africa Anti-VEGF Therapy for Cancer Forecast by Region (2027-2032)
10.5.1 Egypt Market Anti-VEGF Therapy for Cancer Forecast
10.5.2 South Africa Market Anti-VEGF Therapy for Cancer Forecast
10.5.3 Israel Market Anti-VEGF Therapy for Cancer Forecast
10.5.4 Turkey Market Anti-VEGF Therapy for Cancer Forecast
10.6 Global Anti-VEGF Therapy for Cancer Forecast by Type (2027-2032)
10.7 Global Anti-VEGF Therapy for Cancer Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Anti-VEGF Therapy for Cancer Forecast
11 KEY PLAYERS ANALYSIS
11.1 Sanofi
11.1.1 Sanofi Company Information
11.1.2 Sanofi Anti-VEGF Therapy for Cancer Product Offered
11.1.3 Sanofi Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Sanofi Main Business Overview
11.1.5 Sanofi Latest Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Company Information
11.2.2 Eli Lilly Anti-VEGF Therapy for Cancer Product Offered
11.2.3 Eli Lilly Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Eli Lilly Main Business Overview
11.2.5 Eli Lilly Latest Developments
11.3 Roche
11.3.1 Roche Company Information
11.3.2 Roche Anti-VEGF Therapy for Cancer Product Offered
11.3.3 Roche Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Roche Main Business Overview
11.3.5 Roche Latest Developments
11.4 Bayer
11.4.1 Bayer Company Information
11.4.2 Bayer Anti-VEGF Therapy for Cancer Product Offered
11.4.3 Bayer Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Bayer Main Business Overview
11.4.5 Bayer Latest Developments
11.5 Pfizer
11.5.1 Pfizer Company Information
11.5.2 Pfizer Anti-VEGF Therapy for Cancer Product Offered
11.5.3 Pfizer Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Pfizer Main Business Overview
11.5.5 Pfizer Latest Developments
11.6 Jiangsu Hengrui Pharmaceuticals
11.6.1 Jiangsu Hengrui Pharmaceuticals Company Information
11.6.2 Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Product Offered
11.6.3 Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
11.6.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
11.7 Chia Tai Tianqing
11.7.1 Chia Tai Tianqing Company Information
11.7.2 Chia Tai Tianqing Anti-VEGF Therapy for Cancer Product Offered
11.7.3 Chia Tai Tianqing Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Chia Tai Tianqing Main Business Overview
11.7.5 Chia Tai Tianqing Latest Developments
11.8 Novartis
11.8.1 Novartis Company Information
11.8.2 Novartis Anti-VEGF Therapy for Cancer Product Offered
11.8.3 Novartis Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Novartis Main Business Overview
11.8.5 Novartis Latest Developments
11.9 AstraZeneca
11.9.1 AstraZeneca Company Information
11.9.2 AstraZeneca Anti-VEGF Therapy for Cancer Product Offered
11.9.3 AstraZeneca Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 AstraZeneca Main Business Overview
11.9.5 AstraZeneca Latest Developments
11.10 Exelixis
11.10.1 Exelixis Company Information
11.10.2 Exelixis Anti-VEGF Therapy for Cancer Product Offered
11.10.3 Exelixis Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Exelixis Main Business Overview
11.10.5 Exelixis Latest Developments
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Company Information
11.11.2 Boehringer Ingelheim Anti-VEGF Therapy for Cancer Product Offered
11.11.3 Boehringer Ingelheim Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Boehringer Ingelheim Main Business Overview
11.11.5 Boehringer Ingelheim Latest Developments
11.12 Eisai
11.12.1 Eisai Company Information
11.12.2 Eisai Anti-VEGF Therapy for Cancer Product Offered
11.12.3 Eisai Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Eisai Main Business Overview
11.12.5 Eisai Latest Developments
11.13 Janssen Biotech
11.13.1 Janssen Biotech Company Information
11.13.2 Janssen Biotech Anti-VEGF Therapy for Cancer Product Offered
11.13.3 Janssen Biotech Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Janssen Biotech Main Business Overview
11.13.5 Janssen Biotech Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Anti-VEGF Therapy for Cancer Market Size (2021-2032)
2.1.2 Anti-VEGF Therapy for Cancer Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Anti-VEGF Therapy for Cancer by Country/Region (2021, 2025 & 2032)
2.2 Anti-VEGF Therapy for Cancer Segment by Type
2.2.1 VEGF Inhibitors
2.2.2 VEGFR Inhibitors
2.2.3 Anti-VEGF Therapy for Cancer Market Size by Type
2.2.3.1 Anti-VEGF Therapy for Cancer Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.3.2 Global Anti-VEGF Therapy for Cancer Market Size Market Share by Type (2021-2026)
2.3 Anti-VEGF Therapy for Cancer Segment by Application
2.3.1 Colorectal Cancer
2.3.2 Non-small Cell Lung Cancer
2.3.3 Renal Cell Carcinoma
2.3.4 Cervical Cancer
2.3.5 Medullary Thyroid Cancer
2.3.6 Other
2.3.7 Anti-VEGF Therapy for Cancer Market Size by Application
2.3.7.1 Anti-VEGF Therapy for Cancer Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.7.2 Global Anti-VEGF Therapy for Cancer Market Size Market Share by Application (2021-2026)
3 ANTI-VEGF THERAPY FOR CANCER MARKET SIZE BY PLAYER
3.1 Anti-VEGF Therapy for Cancer Market Size Market Share by Player
3.1.1 Global Anti-VEGF Therapy for Cancer Revenue by Player (2021-2026)
3.1.2 Global Anti-VEGF Therapy for Cancer Revenue Market Share by Player (2021-2026)
3.2 Global Anti-VEGF Therapy for Cancer Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ANTI-VEGF THERAPY FOR CANCER BY REGION
4.1 Anti-VEGF Therapy for Cancer Market Size by Region (2021-2026)
4.2 Global Anti-VEGF Therapy for Cancer Annual Revenue by Country/Region (2021-2026)
4.3 Americas Anti-VEGF Therapy for Cancer Market Size Growth (2021-2026)
4.4 APAC Anti-VEGF Therapy for Cancer Market Size Growth (2021-2026)
4.5 Europe Anti-VEGF Therapy for Cancer Market Size Growth (2021-2026)
4.6 Middle East & Africa Anti-VEGF Therapy for Cancer Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026)
5.2 Americas Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026)
5.3 Americas Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Anti-VEGF Therapy for Cancer Market Size by Region (2021-2026)
6.2 APAC Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026)
6.3 APAC Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026)
7.2 Europe Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026)
7.3 Europe Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Anti-VEGF Therapy for Cancer by Region (2021-2026)
8.2 Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026)
8.3 Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ANTI-VEGF THERAPY FOR CANCER MARKET FORECAST
10.1 Global Anti-VEGF Therapy for Cancer Forecast by Region (2027-2032)
10.1.1 Global Anti-VEGF Therapy for Cancer Forecast by Region (2027-2032)
10.1.2 Americas Anti-VEGF Therapy for Cancer Forecast
10.1.3 APAC Anti-VEGF Therapy for Cancer Forecast
10.1.4 Europe Anti-VEGF Therapy for Cancer Forecast
10.1.5 Middle East & Africa Anti-VEGF Therapy for Cancer Forecast
10.2 Americas Anti-VEGF Therapy for Cancer Forecast by Country (2027-2032)
10.2.1 United States Market Anti-VEGF Therapy for Cancer Forecast
10.2.2 Canada Market Anti-VEGF Therapy for Cancer Forecast
10.2.3 Mexico Market Anti-VEGF Therapy for Cancer Forecast
10.2.4 Brazil Market Anti-VEGF Therapy for Cancer Forecast
10.3 APAC Anti-VEGF Therapy for Cancer Forecast by Region (2027-2032)
10.3.1 China Anti-VEGF Therapy for Cancer Market Forecast
10.3.2 Japan Market Anti-VEGF Therapy for Cancer Forecast
10.3.3 Korea Market Anti-VEGF Therapy for Cancer Forecast
10.3.4 Southeast Asia Market Anti-VEGF Therapy for Cancer Forecast
10.3.5 India Market Anti-VEGF Therapy for Cancer Forecast
10.3.6 Australia Market Anti-VEGF Therapy for Cancer Forecast
10.4 Europe Anti-VEGF Therapy for Cancer Forecast by Country (2027-2032)
10.4.1 Germany Market Anti-VEGF Therapy for Cancer Forecast
10.4.2 France Market Anti-VEGF Therapy for Cancer Forecast
10.4.3 UK Market Anti-VEGF Therapy for Cancer Forecast
10.4.4 Italy Market Anti-VEGF Therapy for Cancer Forecast
10.4.5 Russia Market Anti-VEGF Therapy for Cancer Forecast
10.5 Middle East & Africa Anti-VEGF Therapy for Cancer Forecast by Region (2027-2032)
10.5.1 Egypt Market Anti-VEGF Therapy for Cancer Forecast
10.5.2 South Africa Market Anti-VEGF Therapy for Cancer Forecast
10.5.3 Israel Market Anti-VEGF Therapy for Cancer Forecast
10.5.4 Turkey Market Anti-VEGF Therapy for Cancer Forecast
10.6 Global Anti-VEGF Therapy for Cancer Forecast by Type (2027-2032)
10.7 Global Anti-VEGF Therapy for Cancer Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Anti-VEGF Therapy for Cancer Forecast
11 KEY PLAYERS ANALYSIS
11.1 Sanofi
11.1.1 Sanofi Company Information
11.1.2 Sanofi Anti-VEGF Therapy for Cancer Product Offered
11.1.3 Sanofi Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Sanofi Main Business Overview
11.1.5 Sanofi Latest Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Company Information
11.2.2 Eli Lilly Anti-VEGF Therapy for Cancer Product Offered
11.2.3 Eli Lilly Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Eli Lilly Main Business Overview
11.2.5 Eli Lilly Latest Developments
11.3 Roche
11.3.1 Roche Company Information
11.3.2 Roche Anti-VEGF Therapy for Cancer Product Offered
11.3.3 Roche Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Roche Main Business Overview
11.3.5 Roche Latest Developments
11.4 Bayer
11.4.1 Bayer Company Information
11.4.2 Bayer Anti-VEGF Therapy for Cancer Product Offered
11.4.3 Bayer Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Bayer Main Business Overview
11.4.5 Bayer Latest Developments
11.5 Pfizer
11.5.1 Pfizer Company Information
11.5.2 Pfizer Anti-VEGF Therapy for Cancer Product Offered
11.5.3 Pfizer Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Pfizer Main Business Overview
11.5.5 Pfizer Latest Developments
11.6 Jiangsu Hengrui Pharmaceuticals
11.6.1 Jiangsu Hengrui Pharmaceuticals Company Information
11.6.2 Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Product Offered
11.6.3 Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Jiangsu Hengrui Pharmaceuticals Main Business Overview
11.6.5 Jiangsu Hengrui Pharmaceuticals Latest Developments
11.7 Chia Tai Tianqing
11.7.1 Chia Tai Tianqing Company Information
11.7.2 Chia Tai Tianqing Anti-VEGF Therapy for Cancer Product Offered
11.7.3 Chia Tai Tianqing Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Chia Tai Tianqing Main Business Overview
11.7.5 Chia Tai Tianqing Latest Developments
11.8 Novartis
11.8.1 Novartis Company Information
11.8.2 Novartis Anti-VEGF Therapy for Cancer Product Offered
11.8.3 Novartis Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Novartis Main Business Overview
11.8.5 Novartis Latest Developments
11.9 AstraZeneca
11.9.1 AstraZeneca Company Information
11.9.2 AstraZeneca Anti-VEGF Therapy for Cancer Product Offered
11.9.3 AstraZeneca Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 AstraZeneca Main Business Overview
11.9.5 AstraZeneca Latest Developments
11.10 Exelixis
11.10.1 Exelixis Company Information
11.10.2 Exelixis Anti-VEGF Therapy for Cancer Product Offered
11.10.3 Exelixis Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Exelixis Main Business Overview
11.10.5 Exelixis Latest Developments
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Company Information
11.11.2 Boehringer Ingelheim Anti-VEGF Therapy for Cancer Product Offered
11.11.3 Boehringer Ingelheim Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Boehringer Ingelheim Main Business Overview
11.11.5 Boehringer Ingelheim Latest Developments
11.12 Eisai
11.12.1 Eisai Company Information
11.12.2 Eisai Anti-VEGF Therapy for Cancer Product Offered
11.12.3 Eisai Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Eisai Main Business Overview
11.12.5 Eisai Latest Developments
11.13 Janssen Biotech
11.13.1 Janssen Biotech Company Information
11.13.2 Janssen Biotech Anti-VEGF Therapy for Cancer Product Offered
11.13.3 Janssen Biotech Anti-VEGF Therapy for Cancer Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Janssen Biotech Main Business Overview
11.13.5 Janssen Biotech Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Anti-VEGF Therapy for Cancer Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Anti-VEGF Therapy for Cancer Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of VEGF Inhibitors
Table 4. Major Players of VEGFR Inhibitors
Table 5. Anti-VEGF Therapy for Cancer Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Anti-VEGF Therapy for Cancer Market Size Market Share by Type (2021-2026)
Table 8. Anti-VEGF Therapy for Cancer Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 10. Global Anti-VEGF Therapy for Cancer Market Size Market Share by Application (2021-2026)
Table 11. Global Anti-VEGF Therapy for Cancer Revenue by Player (2021-2026) & ($ millions)
Table 12. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Player (2021-2026)
Table 13. Anti-VEGF Therapy for Cancer Key Players Head office and Products Offered
Table 14. Anti-VEGF Therapy for Cancer Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Anti-VEGF Therapy for Cancer Market Size by Region (2021-2026) & ($ millions)
Table 18. Global Anti-VEGF Therapy for Cancer Market Size Market Share by Region (2021-2026)
Table 19. Global Anti-VEGF Therapy for Cancer Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas Anti-VEGF Therapy for Cancer Market Size Market Share by Country (2021-2026)
Table 23. Americas Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas Anti-VEGF Therapy for Cancer Market Size Market Share by Type (2021-2026)
Table 25. Americas Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas Anti-VEGF Therapy for Cancer Market Size Market Share by Application (2021-2026)
Table 27. APAC Anti-VEGF Therapy for Cancer Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC Anti-VEGF Therapy for Cancer Market Size Market Share by Region (2021-2026)
Table 29. APAC Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe Anti-VEGF Therapy for Cancer Market Size Market Share by Country (2021-2026)
Table 33. Europe Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Anti-VEGF Therapy for Cancer
Table 39. Key Market Challenges & Risks of Anti-VEGF Therapy for Cancer
Table 40. Key Industry Trends of Anti-VEGF Therapy for Cancer
Table 41. Global Anti-VEGF Therapy for Cancer Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global Anti-VEGF Therapy for Cancer Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global Anti-VEGF Therapy for Cancer Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global Anti-VEGF Therapy for Cancer Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. Sanofi Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 46. Sanofi Anti-VEGF Therapy for Cancer Product Offered
Table 47. Sanofi Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. Sanofi Main Business
Table 49. Sanofi Latest Developments
Table 50. Eli Lilly Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 51. Eli Lilly Anti-VEGF Therapy for Cancer Product Offered
Table 52. Eli Lilly Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. Eli Lilly Main Business
Table 54. Eli Lilly Latest Developments
Table 55. Roche Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 56. Roche Anti-VEGF Therapy for Cancer Product Offered
Table 57. Roche Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Roche Main Business
Table 59. Roche Latest Developments
Table 60. Bayer Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 61. Bayer Anti-VEGF Therapy for Cancer Product Offered
Table 62. Bayer Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Bayer Main Business
Table 64. Bayer Latest Developments
Table 65. Pfizer Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 66. Pfizer Anti-VEGF Therapy for Cancer Product Offered
Table 67. Pfizer Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Pfizer Main Business
Table 69. Pfizer Latest Developments
Table 70. Jiangsu Hengrui Pharmaceuticals Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 71. Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Product Offered
Table 72. Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Jiangsu Hengrui Pharmaceuticals Main Business
Table 74. Jiangsu Hengrui Pharmaceuticals Latest Developments
Table 75. Chia Tai Tianqing Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 76. Chia Tai Tianqing Anti-VEGF Therapy for Cancer Product Offered
Table 77. Chia Tai Tianqing Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Chia Tai Tianqing Main Business
Table 79. Chia Tai Tianqing Latest Developments
Table 80. Novartis Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 81. Novartis Anti-VEGF Therapy for Cancer Product Offered
Table 82. Novartis Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Novartis Main Business
Table 84. Novartis Latest Developments
Table 85. AstraZeneca Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 86. AstraZeneca Anti-VEGF Therapy for Cancer Product Offered
Table 87. AstraZeneca Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. AstraZeneca Main Business
Table 89. AstraZeneca Latest Developments
Table 90. Exelixis Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 91. Exelixis Anti-VEGF Therapy for Cancer Product Offered
Table 92. Exelixis Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Exelixis Main Business
Table 94. Exelixis Latest Developments
Table 95. Boehringer Ingelheim Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 96. Boehringer Ingelheim Anti-VEGF Therapy for Cancer Product Offered
Table 97. Boehringer Ingelheim Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Boehringer Ingelheim Main Business
Table 99. Boehringer Ingelheim Latest Developments
Table 100. Eisai Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 101. Eisai Anti-VEGF Therapy for Cancer Product Offered
Table 102. Eisai Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Eisai Main Business
Table 104. Eisai Latest Developments
Table 105. Janssen Biotech Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 106. Janssen Biotech Anti-VEGF Therapy for Cancer Product Offered
Table 107. Janssen Biotech Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Janssen Biotech Main Business
Table 109. Janssen Biotech Latest Developments
Table 1. Anti-VEGF Therapy for Cancer Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Anti-VEGF Therapy for Cancer Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of VEGF Inhibitors
Table 4. Major Players of VEGFR Inhibitors
Table 5. Anti-VEGF Therapy for Cancer Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 6. Global Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 7. Global Anti-VEGF Therapy for Cancer Market Size Market Share by Type (2021-2026)
Table 8. Anti-VEGF Therapy for Cancer Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 9. Global Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 10. Global Anti-VEGF Therapy for Cancer Market Size Market Share by Application (2021-2026)
Table 11. Global Anti-VEGF Therapy for Cancer Revenue by Player (2021-2026) & ($ millions)
Table 12. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Player (2021-2026)
Table 13. Anti-VEGF Therapy for Cancer Key Players Head office and Products Offered
Table 14. Anti-VEGF Therapy for Cancer Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Anti-VEGF Therapy for Cancer Market Size by Region (2021-2026) & ($ millions)
Table 18. Global Anti-VEGF Therapy for Cancer Market Size Market Share by Region (2021-2026)
Table 19. Global Anti-VEGF Therapy for Cancer Revenue by Country/Region (2021-2026) & ($ millions)
Table 20. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Country/Region (2021-2026)
Table 21. Americas Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026) & ($ millions)
Table 22. Americas Anti-VEGF Therapy for Cancer Market Size Market Share by Country (2021-2026)
Table 23. Americas Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 24. Americas Anti-VEGF Therapy for Cancer Market Size Market Share by Type (2021-2026)
Table 25. Americas Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 26. Americas Anti-VEGF Therapy for Cancer Market Size Market Share by Application (2021-2026)
Table 27. APAC Anti-VEGF Therapy for Cancer Market Size by Region (2021-2026) & ($ millions)
Table 28. APAC Anti-VEGF Therapy for Cancer Market Size Market Share by Region (2021-2026)
Table 29. APAC Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 30. APAC Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 31. Europe Anti-VEGF Therapy for Cancer Market Size by Country (2021-2026) & ($ millions)
Table 32. Europe Anti-VEGF Therapy for Cancer Market Size Market Share by Country (2021-2026)
Table 33. Europe Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 34. Europe Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 35. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Region (2021-2026) & ($ millions)
Table 36. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Type (2021-2026) & ($ millions)
Table 37. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size by Application (2021-2026) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Anti-VEGF Therapy for Cancer
Table 39. Key Market Challenges & Risks of Anti-VEGF Therapy for Cancer
Table 40. Key Industry Trends of Anti-VEGF Therapy for Cancer
Table 41. Global Anti-VEGF Therapy for Cancer Market Size Forecast by Region (2027-2032) & ($ millions)
Table 42. Global Anti-VEGF Therapy for Cancer Market Size Market Share Forecast by Region (2027-2032)
Table 43. Global Anti-VEGF Therapy for Cancer Market Size Forecast by Type (2027-2032) & ($ millions)
Table 44. Global Anti-VEGF Therapy for Cancer Market Size Forecast by Application (2027-2032) & ($ millions)
Table 45. Sanofi Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 46. Sanofi Anti-VEGF Therapy for Cancer Product Offered
Table 47. Sanofi Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 48. Sanofi Main Business
Table 49. Sanofi Latest Developments
Table 50. Eli Lilly Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 51. Eli Lilly Anti-VEGF Therapy for Cancer Product Offered
Table 52. Eli Lilly Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 53. Eli Lilly Main Business
Table 54. Eli Lilly Latest Developments
Table 55. Roche Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 56. Roche Anti-VEGF Therapy for Cancer Product Offered
Table 57. Roche Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 58. Roche Main Business
Table 59. Roche Latest Developments
Table 60. Bayer Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 61. Bayer Anti-VEGF Therapy for Cancer Product Offered
Table 62. Bayer Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Bayer Main Business
Table 64. Bayer Latest Developments
Table 65. Pfizer Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 66. Pfizer Anti-VEGF Therapy for Cancer Product Offered
Table 67. Pfizer Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Pfizer Main Business
Table 69. Pfizer Latest Developments
Table 70. Jiangsu Hengrui Pharmaceuticals Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 71. Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Product Offered
Table 72. Jiangsu Hengrui Pharmaceuticals Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Jiangsu Hengrui Pharmaceuticals Main Business
Table 74. Jiangsu Hengrui Pharmaceuticals Latest Developments
Table 75. Chia Tai Tianqing Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 76. Chia Tai Tianqing Anti-VEGF Therapy for Cancer Product Offered
Table 77. Chia Tai Tianqing Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Chia Tai Tianqing Main Business
Table 79. Chia Tai Tianqing Latest Developments
Table 80. Novartis Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 81. Novartis Anti-VEGF Therapy for Cancer Product Offered
Table 82. Novartis Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Novartis Main Business
Table 84. Novartis Latest Developments
Table 85. AstraZeneca Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 86. AstraZeneca Anti-VEGF Therapy for Cancer Product Offered
Table 87. AstraZeneca Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. AstraZeneca Main Business
Table 89. AstraZeneca Latest Developments
Table 90. Exelixis Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 91. Exelixis Anti-VEGF Therapy for Cancer Product Offered
Table 92. Exelixis Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Exelixis Main Business
Table 94. Exelixis Latest Developments
Table 95. Boehringer Ingelheim Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 96. Boehringer Ingelheim Anti-VEGF Therapy for Cancer Product Offered
Table 97. Boehringer Ingelheim Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Boehringer Ingelheim Main Business
Table 99. Boehringer Ingelheim Latest Developments
Table 100. Eisai Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 101. Eisai Anti-VEGF Therapy for Cancer Product Offered
Table 102. Eisai Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Eisai Main Business
Table 104. Eisai Latest Developments
Table 105. Janssen Biotech Details, Company Type, Anti-VEGF Therapy for Cancer Area Served and Its Competitors
Table 106. Janssen Biotech Anti-VEGF Therapy for Cancer Product Offered
Table 107. Janssen Biotech Anti-VEGF Therapy for Cancer Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Janssen Biotech Main Business
Table 109. Janssen Biotech Latest Developments
LIST OF FIGURES
Figure 1. Anti-VEGF Therapy for Cancer Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Anti-VEGF Therapy for Cancer Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Anti-VEGF Therapy for Cancer Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Anti-VEGF Therapy for Cancer Sales Market Share by Country/Region (2025)
Figure 8. Anti-VEGF Therapy for Cancer Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Anti-VEGF Therapy for Cancer Market Size Market Share by Type in 2025
Figure 10. Anti-VEGF Therapy for Cancer in Colorectal Cancer
Figure 11. Global Anti-VEGF Therapy for Cancer Market: Colorectal Cancer (2021-2026) & ($ millions)
Figure 12. Anti-VEGF Therapy for Cancer in Non-small Cell Lung Cancer
Figure 13. Global Anti-VEGF Therapy for Cancer Market: Non-small Cell Lung Cancer (2021-2026) & ($ millions)
Figure 14. Anti-VEGF Therapy for Cancer in Renal Cell Carcinoma
Figure 15. Global Anti-VEGF Therapy for Cancer Market: Renal Cell Carcinoma (2021-2026) & ($ millions)
Figure 16. Anti-VEGF Therapy for Cancer in Cervical Cancer
Figure 17. Global Anti-VEGF Therapy for Cancer Market: Cervical Cancer (2021-2026) & ($ millions)
Figure 18. Anti-VEGF Therapy for Cancer in Medullary Thyroid Cancer
Figure 19. Global Anti-VEGF Therapy for Cancer Market: Medullary Thyroid Cancer (2021-2026) & ($ millions)
Figure 20. Anti-VEGF Therapy for Cancer in Other
Figure 21. Global Anti-VEGF Therapy for Cancer Market: Other (2021-2026) & ($ millions)
Figure 22. Global Anti-VEGF Therapy for Cancer Market Size Market Share by Application in 2025
Figure 23. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Player in 2025
Figure 24. Global Anti-VEGF Therapy for Cancer Market Size Market Share by Region (2021-2026)
Figure 25. Americas Anti-VEGF Therapy for Cancer Market Size 2021-2026 ($ millions)
Figure 26. APAC Anti-VEGF Therapy for Cancer Market Size 2021-2026 ($ millions)
Figure 27. Europe Anti-VEGF Therapy for Cancer Market Size 2021-2026 ($ millions)
Figure 28. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size 2021-2026 ($ millions)
Figure 29. Americas Anti-VEGF Therapy for Cancer Value Market Share by Country in 2025
Figure 30. United States Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 31. Canada Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 32. Mexico Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 33. Brazil Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 34. APAC Anti-VEGF Therapy for Cancer Market Size Market Share by Region in 2025
Figure 35. APAC Anti-VEGF Therapy for Cancer Market Size Market Share by Type (2021-2026)
Figure 36. APAC Anti-VEGF Therapy for Cancer Market Size Market Share by Application (2021-2026)
Figure 37. China Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 38. Japan Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 39. South Korea Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 40. Southeast Asia Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 41. India Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 42. Australia Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 43. Europe Anti-VEGF Therapy for Cancer Market Size Market Share by Country in 2025
Figure 44. Europe Anti-VEGF Therapy for Cancer Market Size Market Share by Type (2021-2026)
Figure 45. Europe Anti-VEGF Therapy for Cancer Market Size Market Share by Application (2021-2026)
Figure 46. Germany Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 47. France Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 48. UK Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 49. Italy Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 50. Russia Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 51. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size Market Share by Region (2021-2026)
Figure 52. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size Market Share by Type (2021-2026)
Figure 53. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size Market Share by Application (2021-2026)
Figure 54. Egypt Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 55. South Africa Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 56. Israel Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 57. Turkey Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 58. GCC Countries Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 59. Americas Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 60. APAC Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 61. Europe Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 62. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 63. United States Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 64. Canada Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 65. Mexico Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 66. Brazil Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 67. China Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 68. Japan Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 69. Korea Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 70. Southeast Asia Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 71. India Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 72. Australia Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 73. Germany Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 74. France Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 75. UK Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 76. Italy Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 77. Russia Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 78. Egypt Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 79. South Africa Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 80. Israel Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 81. Turkey Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 82. Global Anti-VEGF Therapy for Cancer Market Size Market Share Forecast by Type (2027-2032)
Figure 83. Global Anti-VEGF Therapy for Cancer Market Size Market Share Forecast by Application (2027-2032)
Figure 84. GCC Countries Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 1. Anti-VEGF Therapy for Cancer Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Anti-VEGF Therapy for Cancer Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Anti-VEGF Therapy for Cancer Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Anti-VEGF Therapy for Cancer Sales Market Share by Country/Region (2025)
Figure 8. Anti-VEGF Therapy for Cancer Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Anti-VEGF Therapy for Cancer Market Size Market Share by Type in 2025
Figure 10. Anti-VEGF Therapy for Cancer in Colorectal Cancer
Figure 11. Global Anti-VEGF Therapy for Cancer Market: Colorectal Cancer (2021-2026) & ($ millions)
Figure 12. Anti-VEGF Therapy for Cancer in Non-small Cell Lung Cancer
Figure 13. Global Anti-VEGF Therapy for Cancer Market: Non-small Cell Lung Cancer (2021-2026) & ($ millions)
Figure 14. Anti-VEGF Therapy for Cancer in Renal Cell Carcinoma
Figure 15. Global Anti-VEGF Therapy for Cancer Market: Renal Cell Carcinoma (2021-2026) & ($ millions)
Figure 16. Anti-VEGF Therapy for Cancer in Cervical Cancer
Figure 17. Global Anti-VEGF Therapy for Cancer Market: Cervical Cancer (2021-2026) & ($ millions)
Figure 18. Anti-VEGF Therapy for Cancer in Medullary Thyroid Cancer
Figure 19. Global Anti-VEGF Therapy for Cancer Market: Medullary Thyroid Cancer (2021-2026) & ($ millions)
Figure 20. Anti-VEGF Therapy for Cancer in Other
Figure 21. Global Anti-VEGF Therapy for Cancer Market: Other (2021-2026) & ($ millions)
Figure 22. Global Anti-VEGF Therapy for Cancer Market Size Market Share by Application in 2025
Figure 23. Global Anti-VEGF Therapy for Cancer Revenue Market Share by Player in 2025
Figure 24. Global Anti-VEGF Therapy for Cancer Market Size Market Share by Region (2021-2026)
Figure 25. Americas Anti-VEGF Therapy for Cancer Market Size 2021-2026 ($ millions)
Figure 26. APAC Anti-VEGF Therapy for Cancer Market Size 2021-2026 ($ millions)
Figure 27. Europe Anti-VEGF Therapy for Cancer Market Size 2021-2026 ($ millions)
Figure 28. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size 2021-2026 ($ millions)
Figure 29. Americas Anti-VEGF Therapy for Cancer Value Market Share by Country in 2025
Figure 30. United States Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 31. Canada Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 32. Mexico Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 33. Brazil Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 34. APAC Anti-VEGF Therapy for Cancer Market Size Market Share by Region in 2025
Figure 35. APAC Anti-VEGF Therapy for Cancer Market Size Market Share by Type (2021-2026)
Figure 36. APAC Anti-VEGF Therapy for Cancer Market Size Market Share by Application (2021-2026)
Figure 37. China Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 38. Japan Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 39. South Korea Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 40. Southeast Asia Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 41. India Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 42. Australia Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 43. Europe Anti-VEGF Therapy for Cancer Market Size Market Share by Country in 2025
Figure 44. Europe Anti-VEGF Therapy for Cancer Market Size Market Share by Type (2021-2026)
Figure 45. Europe Anti-VEGF Therapy for Cancer Market Size Market Share by Application (2021-2026)
Figure 46. Germany Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 47. France Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 48. UK Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 49. Italy Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 50. Russia Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 51. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size Market Share by Region (2021-2026)
Figure 52. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size Market Share by Type (2021-2026)
Figure 53. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size Market Share by Application (2021-2026)
Figure 54. Egypt Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 55. South Africa Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 56. Israel Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 57. Turkey Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 58. GCC Countries Anti-VEGF Therapy for Cancer Market Size Growth 2021-2026 ($ millions)
Figure 59. Americas Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 60. APAC Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 61. Europe Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 62. Middle East & Africa Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 63. United States Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 64. Canada Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 65. Mexico Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 66. Brazil Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 67. China Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 68. Japan Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 69. Korea Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 70. Southeast Asia Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 71. India Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 72. Australia Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 73. Germany Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 74. France Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 75. UK Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 76. Italy Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 77. Russia Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 78. Egypt Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 79. South Africa Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 80. Israel Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 81. Turkey Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
Figure 82. Global Anti-VEGF Therapy for Cancer Market Size Market Share Forecast by Type (2027-2032)
Figure 83. Global Anti-VEGF Therapy for Cancer Market Size Market Share Forecast by Application (2027-2032)
Figure 84. GCC Countries Anti-VEGF Therapy for Cancer Market Size 2027-2032 ($ millions)
